Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Drug Development - The proposed indication for HRS-4642 is in combination with gemcitabine and albumin-bound paclitaxel [1] - The total research and development investment for the related project has reached approximately 254 million yuan [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1]